[Potential hemoprotective effect of dicarbamin in chemoradiotherapy for malignant tumors].

To improve the results of treatment of locally advanced malignant tumors we performed different types of combined radio- and chemotherapy, which are mostly applied in neo- and/or adjuvant or parallel regimens, and have significant toxic effect on hemopoiesis. For the last years we have used dicarbamin, a natural hemoprotector from the group of pseudopeptides. Good outcomes have been achieved in its ability to reduce frequency of hematological complications in patients with locally advanced lung cancer and Hodgkin's disease treated by combined radio- and chemotherapy.

[The usefulness of neo- and adjuvant therapy in the treatment of cutaneous melanoma].

One hundred-thirty seven patients with recurrences and metastases of skin melanoma (stage II-III) were divided into four groups in a retrospective study. In group I, there was no adjuvant therapy (47); it was given for 35 +/- 5 days after surgery in group II (31); for 1-2 days after surgery in group III (31). In group IV, neoadjuvant therapy (NAT) was administered by way of preparing for surgery and adjuvant therapy (41).

[Clinico-morpho-sonographic parallels in skin melanoma].

Data on sonographic features of different variants of skin melanoma are presented. Relationship between skin to tumor thickness ratio and invasion depth (Clark) or tumor thickness (Breslow) were found. Tumor extent was effectively identified by ultrasound tomography of primary focus preoperatively.

[Radiotherapy in multiple modality treatment of children with nephroblastoma].

The role of radiotherapy in multiple modality treatment of Wilms' tumor is evaluated in 225 children aged 3 months to 11.5 years (mean age 3.5 years) with stage III-IV.